Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial-Reference-Cited by-同舟云学术

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

Published:2016-05 Issue:5 Volume:69 Page:866-874
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Tannir Nizar M.,Jonasch Eric,Albiges Laurence,Altinmakas Emre,Ng Chaan S.,Matin Surena F.,Wang Xuemei,Qiao Wei,Dubauskas Lim Zita,Tamboli Pheroze,Rao Priya,Sircar Kanishka,Karam Jose A.,McDermott David F.,Wood Christopher G.,Choueiri Toni K.

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. Renal-cell carcinoma;Cohen;N Engl J Med,2005

2. 2009 update on the classification of renal epithelial tumors in adults;Lopez-Beltran;Int J Urol,2009

3. NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Kidney cancer, version 3.2014. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed June 23, 2014.

4. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Escudier;Ann Oncol,2014

5. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria;Kroeger;Cancer,2013

Cited by 290 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Clinicopathological Characteristics and Prognosis of 55 Patients With TFE3-Rearranged Renal Cell Carcinomas;Clinical Genitourinary Cancer;2024-10

2. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma;Journal of Chemotherapy;2024-09-10

3. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma;Journal of Clinical Oncology;2024-09-10

4. Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan;International Journal of Clinical Oncology;2024-09-02

5. Changes in outcome of patients with advanced non-clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno-oncology era;International Journal of Clinical Oncology;2024-08-14